Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A three-part, double-blind, placebo-controlled, phase I/Ib study of the safety, tolerability and pharmacokinetics of single and multiple ascending doses of IMU-935 in healthy volunteers and Psoriasis Patients

Next Previous
X
Search
Trial Profile

A three-part, double-blind, placebo-controlled, phase I/Ib study of the safety, tolerability and pharmacokinetics of single and multiple ascending doses of IMU-935 in healthy volunteers and Psoriasis Patients

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Izumerogant (Primary)
  • Indications Autoimmune disorders; Psoriasis
  • Focus Adverse reactions; Proof of concept
  • Sponsors Immunic Australia

    • Most Recent Events

    • 03 Nov 2022 According to an Immunic media release, the company plans to provide further updates and guidance on potential next steps for this trial of IMU-935 in patients with moderate-to-severe psoriasis in the first quarter of 2023.
    • 20 Oct 2022 Interim results presented in an Immunic media release.
    • 04 Aug 2022 According to an Immunic media release, recruitment of part C is ongoing in Australia, New Zealand and Bulgaria and initial clinical activity data from part C is expected in the fourth quarter of this year.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top